Dr. Heath-Chiozzi joined Celldex in October 2017 as Senior Vice President, Regulatory Affairs. Prior to joining Celldex, she was Vice President, Global Submissions and Regulatory Policy at Bristol-Myers Squibb Company, where she provided executive global regulatory strategy leading to nine product approvals. Previously, she served as Vice President, Global Regulatory Strategy, contributing to several business units including oncology, immunology, virology and genetically defined diseases. While at Bristol-Myers Squibb, she supported the global launches of several successful therapies in the areas of oncology, inflammation and infectious disease, including Yervoy®, Erbitux®, Orencia®, Sprycel®, Daklinza®, Sunvepra, Baraclude®, Atripla® and Reyataz®. From 1995 to 2003, Dr. Heath-Chiozzi served in roles of increasing responsibility at Abbott Laboratories, including Medical Director, Pharmacogenetics; Senior Director, Global Marketed Product Development and Outcomes Research; and Global Project Head, Abbott/Millennium Obesity/Diabetes Alliance. Before joining Abbott, she was appointed to the University of Hawaii John A. Burns School of Medicine, where she served as Assistant Professor, and was concurrently Director of the HIV Research Clinical at the Queen’s Medical Center as well as Director of the Women’s Immunology Clinical at the Kapiolani Medical Center for Women and Children, in Honolulu. Dr. Heath-Chiozzi received her B.S. and M.D. from the University of Utah. She received further medical training in internal medicine at Duke University and completed fellowships in infectious disease at Brigham & Women’s Hospital and Dana-Farber Cancer Institute in Boston.
What is Margo Heath-Chiozzi's net worth?
The estimated net worth of Margo Heath-Chiozzi is at least $138,829.58 as of May 30th, 2024. Dr. Heath-Chiozzi owns 7,094 shares of Celldex Therapeutics stock worth more than $138,830 as of March 26th. This net worth estimate does not reflect any other investments that Dr. Heath-Chiozzi may own. Additionally, Dr. Heath-Chiozzi receives a salary of $667,210.00 as SVP at Celldex Therapeutics. Learn More about Margo Heath-Chiozzi's net worth.
How old is Margo Heath-Chiozzi?
Dr. Heath-Chiozzi is currently 67 years old. There are 8 older executives and no younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics is Prof. Joseph P. Schlessinger Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 79 years old. Learn More on Margo Heath-Chiozzi's age.
What is Margo Heath-Chiozzi's salary?
As the SVP of Celldex Therapeutics, Inc., Dr. Heath-Chiozzi earns $667,210.00 per year. There are 4 executives that earn more than Dr. Heath-Chiozzi. The highest earning executive at Celldex Therapeutics is Mr. Anthony S. Marucci M.B.A., Founder, President, CEO & Director, who commands a salary of $1,270,000.00 per year. Learn More on Margo Heath-Chiozzi's salary.
How do I contact Margo Heath-Chiozzi?
The corporate mailing address for Dr. Heath-Chiozzi and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at ir@celldextherapeutics.com. Learn More on Margo Heath-Chiozzi's contact information.
Has Margo Heath-Chiozzi been buying or selling shares of Celldex Therapeutics?
Margo Heath-Chiozzi has not been actively trading shares of Celldex Therapeutics during the past quarter. Most recently, Margo Heath-Chiozzi sold 38,719 shares of the business's stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $34.07, for a transaction totalling $1,319,156.33. Following the completion of the sale, the senior vice president now directly owns 7,094 shares of the company's stock, valued at $241,692.58. Learn More on Margo Heath-Chiozzi's trading history.
Who are Celldex Therapeutics' active insiders?
Are insiders buying or selling shares of Celldex Therapeutics?
In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $308,430.00. In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 266,332 shares worth more than $9,155,821.33. The most recent insider tranaction occured on November, 11th when CEO Anthony S Marucci bought 11,500 shares worth more than $308,430.00. Insiders at Celldex Therapeutics own 3.8% of the company.
Learn More about insider trades at Celldex Therapeutics. Information on this page was last updated on 11/11/2024.
